HER2突变非小细胞肺癌的新兴靶向治疗
HER2突变NSCLC约占所有NSCLC的2%至5%,预后较差。抗体药物偶联物和HER2选择性酪氨酸激酶抑制剂两类靶向治疗在经治患者中显示出确切疗效,其中T-DXd是首个获批的靶向治疗,在约50%患者中产生持久缓解,但需警惕间质性肺病。新型口服TKIs如sevabertinib和zongertinib显示出深度持久缓解,ILD发生率显著更低,尤其是zongertinib耐受性良好。本综述总结了HER2突变NSCLC的分子特征、临床证据及治疗前景。
要点
- T-DXd是首个获批用于HER2突变NSCLC的靶向治疗,约50%患者缓解,需监测ILD。
- 新型HER2 ADCs确认疗效,但ILD为类效应,发生率各异。
- sevabertinib和zongertinib等新型TKIs显示深度持久缓解,ILD率显著更低。
核心结论
- HER2突变NSCLC已有两类靶向治疗显示确切疗效,新型TKIs可能提供更好的耐受性。
研究设计与样本
- 综述,总结HER2突变NSCLC的分子特征、临床特征及靶向治疗的临床和临床前证据。
主要发现
- T-DXd在约50%的HER2突变NSCLC经治患者中产生稳健且持久的缓解。
- 新型HER2 ADCs确认了在该肿瘤类型中的确切疗效,ILD发生率各异。
- sevabertinib和zongertinib等新型口服TKIs显示出深度且持久的缓解。
- zongertinib耐受性良好,不良事件主要为低级别,ILD发生率显著更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HER2-mutant lung cancer represents approximately 2% to 5% of all NSCLCs and is associated with poor prognosis. Two different HER2-targeted therapeutic approaches with different mechanisms of action-antibody-drug conjugates and HER2-selective tyrosine kinase inhibitors (TKIs)-have demonstrated convincing efficacy in pretreated patients. Trastuzumab deruxtecan was the first targeted therapy approved for patients with HER2-mutant NSCLC, demonstrating robust and durable responses in approximately 50% of these patients. Toxicity, although overall manageable, includes an increased risk of interstitial lung disease (ILD), which can be problematic and requires close clinical monitoring. More novel HER2-directed antibody-drug conjugates have confirmed the solid efficacy in this tumor type, revealing variable rates of ILD as a class effect of these agents. However, novel orally available TKIs with higher specificity and inhibitory potency against HER2 than wild-type EGFR such as sevabertinib (a dual HER2/EGFR mutant-selective reversible TKI) or zongertinib (an irreversible HER2-selective TKI that spares EGFR, including mutant EGFR) have further demonstrated deep and durable responses in this disease. Toxicities with these agents are mostly related to EGFR wild-type inhibition, with significantly lower rates of ILD. Consistent with its selectivity and mechanism of action, zongertinib offers a favorable tolerability profile, with mainly low-grade adverse events including those related to wild-type EGFR inhibition. In this review, we first describe the molecular landscape and clinical features of HER2-mutant NSCLC. Then, we summarize the clinical and preclinical evidence of HER2-targeted therapies and provide a forward-looking perspective of the treatment landscape of HER2-mutant NSCLC.
引用
- Del Rio B, Masini S, Cáceres-Galvis C, et al. Emerging Targeted Therapies for HER2-Mutant NSCLC. J Thorac Oncol. 2026. PMID: 42082076. doi:10.1016/j.jtho.2026.103899
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。